AtonRa Partners’s 10x Genomics TXG Stock Holding History

AtonRa Partners’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$420K	Sell	7,498 -796	-10%	-$34.6K	0.84%	51
2023 Q3	$342K	Sell	8,294 -1,088	-12%	-$56.6K	0.72%	68
2023 Q2	$524K	Sell	9,382 -868	-8%	-$47K	0.81%	50
2023 Q1	$572K	Sell	10,250 -1,303	-11%	-$60.8K	0.83%	43
2022 Q4	$421K	Sell	11,553 -3,125	-21%	-$102K	0.54%	81
2022 Q3	$418K	Buy	14,678 +3,649	+33%	+$139K	0.41%	103
2022 Q2	$499K	Buy	11,029 +2,292	+26%	+$119K	0.46%	101
2022 Q1	$665K	Sell	8,737 -1,460	-14%	-$128K	0.36%	99
2021 Q4	$1.52M	Sell	10,197 -4,281	-30%	-$656K	0.53%	67
2021 Q3	$2.11M	Buy	14,478 +1,345	+10%	+$231K	0.7%	59
2021 Q2	$2.57M	Buy	13,133 +360	+3%	+$65.2K	0.94%	50
2021 Q1	$2.31M	Buy	+12,773	New	+$2.21M	1.03%	43

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

AtonRa Partners's TXG Position: Q4 2023 in Review

AtonRa Partners reduced its 10x Genomics (TXG) stake by 9.6% in Q4 2023, selling an estimated $34.6K and leaving 7,498 shares worth $420K. The position accounts for 0.84% of the portfolio, ranked #51.

AtonRa Partners first reported a position in TXG in Q1 2021 and has held it in 12 quarters since. The position peaked at $2.57M in Q2 2021. 275 funds tracked by Wall St. Rank hold TXG as of Q4 2023.

AtonRa Partners held 7,498 shares of 10x Genomics worth $420K as of Q4 2023.
AtonRa Partners sold 796 10x Genomics shares in Q4 2023, an estimated $34.6K.
10x Genomics made up 0.84% of AtonRa Partners's portfolio in Q4 2023, its #51 holding.
AtonRa Partners first reported a position in 10x Genomics in Q1 2021 and has held it in 12 quarters since.
AtonRa Partners's 10x Genomics position peaked at $2.57M in Q2 2021.
275 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2023.

Based on AtonRa Partners's 13F filing for Q4 2023, filed 5 Feb 2024.